Abstract: The present invention relates to the technical field of pharmaceuticals. Specifically, the present invention relates to a halo-allylamine compound, or a pharmaceutically acceptable salt, an ester, a stereoisomer or a tautomer thereof, and a pharmaceutical formulation and a pharmaceutical composition comprising the compounds, and use in preventing and/or treating a disease related to or mediated by the SSAO/VAP-1 protein, wherein R1, R2, R3, R4, R5, R6, L1 and Cy1 are defined in the specification.

Abstract: A method and an equipment for preparing a pultruded polyurethane composite by a polyurethane pultrusion process, and the pultruded polyurethane composite obtained by the method and use thereof are provided.

Abstract: The present application belongs to the technical field of medicines, relates to an NLRP3 inflammasome inhibitor and the uses thereof, and particularly relates to a compound represented by general formula (A) or a pharmaceutically acceptable salt, a stereoisomer and a tautomer thereof. The inhibitor has biological activity on NLRP3 inflammasome, and has important clinical development value for treatment of NLRP3-related diseases.

Abstract: The present invention relates to a pharmaceutical composition of a compound as shown in formula (I) or a pharmaceutically acceptable salt, a stereoisomer, or a crystal form thereof with a programmed cell death protein 1/programmed cell death protein 1 ligand 1 (PD-1/PD-L1) antibody, and a kit thereof and the use thereof in the treatment of cancer diseases, wherein Y, P, W and Ar are as defined in the specification.

Abstract: The present invention belongs to the technical field of medicines, relates to an NLRP3 inflammasome inhibitor and use thereof, and particularly relates to a compound of general formula (I), or a pharmaceutically acceptable salt, a stereoisomer or a tautomer thereof, wherein each group is defined in the specification. Researches show that the compound of general formula (I), or pharmaceutically acceptable salt, the stereoisomer or the tautomer thereof has relatively high biological activity on NLRP3 inflammasomes and has an important clinical development value for the treatment of NLRP3-associated diseases.

Abstract: The present disclosure relates to a cassette and a tissue embedding method using the cassette. The cassette includes a frame, a cover and a base. The frame defines an accommodating cavity through a first face and a second face of the frame arranged oppositely in a first direction. The cover is detachably mounted to the frame. The base is detachably mounted to the frame, and the base and the cover are configured to hold and orient a tissue sample therebetween. The base is slidable relative to the frame in a second direction different from the first direction to open and close the accommodating cavity.

Abstract: Disclosed herein is a syringe pump module with a non-decoupling drive mechanism and motor actuation mechanism to configured to bidirectionally move the non-decoupling drive mechanism.

Abstract: The present invention belongs to the technical field of medicine, and relates in particular to a crystal form of a fibroblast growth factor receptor inhibitor shown in formula (I), and a preparation method therefor.

Abstract: A method and an equipment for preparing a pultruded polyurethane composite by a polyurethane pultrusion process, and the pultruded polyurethane composite obtained by the method and use thereof are provided.

Abstract: Disclosed herein are compositions and methods for treating subjects for pain with opioids while reducing or inhibiting their risk of opioid addiction.

Abstract: The present invention relates to a method for treating a cancer mediated by abnormality of multi-kinases, comprising administrating a compound as represented by formula (I) or a pharmaceutically acceptable salt and stereoisomer thereof, wherein R1, R2, X, Y, P, W, and Ar are as defined in the description. Also provided is a method for treating a cancer mediated by abnormality of multi-kinases, comprising administrating a crystal form I of a compound 4-(5-(2-chlorophenyl)-3-methyl-2,10-dihydropyrazolo[4,3-b]pyrido[4,3-e][1,4]diazepin-8-yl)morpholine, wherein in an X-ray powder diffraction pattern of crystal form I, there are characteristic peaks at 7.4±0.2°, 17.9±0.2°, 18.9±0.2°, 19.4±0.2°, 21.5±0.2°, and 23.7±0.2°.

Abstract: Disclosed herein is a syringe pump module with a non-decoupling drive mechanism and motor actuation mechanism to configured to bidirectionally move the non-decoupling drive mechanism.

Abstract: A sous-vide circulator cooker that sounds an audible alarm when the system raises the temperature of the water to a determined temperature. The sous-vide circulator cooker includes temperature sensors, heaters and a pump to circulator temperature controlled fluids. The system also contains a speaker or buzzer that can play alarms or music when the system comes to a predetermined temperature. In at least one embodiment, the sous-vide circulator can also distinguish between self-heating and user-induced temperature changes, and will sound alarms accordingly.